Potential therapies and diagnosis based on Golgi-targeted nano drug delivery systems

Zhang, Manyue; Xu, Na; Xu, Wenxin; Ling, Guixia; Zhang, Peng

doi:10.1016/j.phrs.2021.105861

Cited by 32 publications

(28 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…So far, most studies of ER–Golgi-targeted nanomedicines mainly focus on the subcellular level [ 88 , 89 ], while the sequentially active-targeted drug delivery systems for cancer treatment remain challenging.…”

Section: Endoplasmic Reticulum/golgi Apparatus Targeting Systemmentioning

confidence: 99%

Sequential Drug Delivery in Targeted Cancer Therapy

Ning

Meng

et al. 2022

Pharmaceutics

View full text Add to dashboard Cite

Cancer is a major public health problem and one of the leading causes of death. However, traditional cancer therapy may damage normal cells and cause side effects. Many targeted drug delivery platforms have been developed to overcome the limitations of the free form of therapeutics and biological barriers. The commonly used cancer cell surface targets are CD44, matrix metalloproteinase-2, folate receptors, etc. Once the drug enters the cell, active delivery of the drug molecule to its final destination is still preferred. The subcellular targeting strategies include using glucocorticoid receptors for nuclear targeting, negative mitochondrial membrane potential and N-acetylgalactosaminyltransferase for Golgi apparatus targeting, etc. Therefore, the most effective way to deliver therapeutic agents is through a sequential drug delivery system that simultaneously achieves cellular- and subcellular-level targeting. The dual-targeting delivery holds great promise for improving therapeutic effects and overcoming drug resistance. This review classifies sequential drug delivery systems based on final targeted organelles. We summarize different targeting strategies and mechanisms and gave examples of each case.

show abstract

Section: Endoplasmic Reticulum/golgi Apparatus Targeting Systemmentioning

confidence: 99%

Sequential Drug Delivery in Targeted Cancer Therapy

Ning

Meng

et al. 2022

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Destabilization of the classical ER-Golgi secretory pathway has been explored in the context of Golgi-targeted pharmacological approaches, and have proven effective in vivo and a few human cancer trials [38]. There are therapeutic advantages by selectively transporting drugs to tumor cells that are Golgi-targeted nano drug delivery systems [39]. Nanoparticles with pH-responsive photothermal ablation agent preferentially accumulate in the acidic Golgi of cancer cells [40].…”

Section: Golgi Complex: Ground Zero For Cancermentioning

confidence: 99%

Pioneering Organelle Structural Biology: Golgi Apparatus Dysfunction in Parkinson’s Disease, Neurodevelopmental Disorders, and Cancer

Gómez¹

2022

Preprint

View full text Add to dashboard Cite

The Golgi complex (GC) dysfunctions in Parkinson’s Disease (PD), neurodevelopmental disorders (NDDs), cancer, and organelle structural biology (OSB) can provide insights into therapeutic targets, gene therapy, and drug design. Primary defects and fragmentation within the GC are implicated in a wide range of neurodegenerative diseases. GC defects typically result in mislocation of proteins, accumulation of undegraded proteins, and impaired glycosylation of proteins. Inhibition of vesicular trafficking by α-synuclein (aSyn) may affect the dopamine-producing neurons and neuromodulators. GC regulates apoptosis during pathological mechanisms of neurological diseases and could provide new avenues in treatments through translation research. PD patients bearing the hereditary E46K disease mutation manifest the clinical picture of parkinsonism. How do we provide high resolution nanoimages of the GC during disease to capture dysfunction? Could we visualize the aSyn traffic jam between vesicles in the organelles ER and GC? OSB is emerging as a field as more technology advances and is more accessible. Structural studies of the GC will advance the field of neurological disease forward with an in depth understanding of dysfunction, fragmentation, and defects. Discoveries of the GC in PD, NDDs, and cancer would break new ground and provide translational medicine data of these diseases. Future research could be visualizing high angle annular dark field-STEM (HADDF-STEM) tomograms, cryogenic electron tomography (cryo-ET), multiplex correlative light and electron microscopy (cryo-CLEM), nanobody-assisted tissue immunostaining for volumetric EM (NATIVE) and using soft X-ray tomography (SXT) and computational reconstruction of the GC.

show abstract

“…Destabilization of the classical ER-Golgi secretory pathway has been explored in the context of Golgi-targeted pharmacological approaches, and have proven effective in vivo and a few human cancer trials [41]. There are therapeutic advantages by selectively transporting drugs to tumor cells that are Golgi-targeted nano drug delivery systems [42]. Nanoparticles with pH-responsive photothermal ablation agent preferentially accumulate in the acidic Golgi of cancer cells [43].…”

Section: Golgi Apparatus: Ground Zero For Cancermentioning

confidence: 99%

Pioneering Organelle Structural Biology: Golgi Apparatus Dysfunction in Parkinson’s Disease, Neurodevelopmental Disorders, and Cancer

Gómez¹

2022

Preprint

View full text Add to dashboard Cite

The Golgi apparatus (GA) dysfunctions in Parkinson’s Disease (PD), neurodevelopmental disorders (NDDs), cancer, and organelle structural biology (OSB) can provide insights into therapeutic targets, gene therapy, and drug design. Primary defects and fragmentation within the GA are implicated in a wide range of neurodegenerative diseases. GA defects typically result in mislocation of proteins, accumulation of undegraded proteins, and impaired glycosylation of proteins. Inhibition of vesicular trafficking by α-synuclein (aSyn) may affect the dopamine-producing neurons and neuromodulators. GA regulates apoptosis during pathological mechanisms of neurological diseases and could provide new avenues in treatments through translation research. PD patients bearing the hereditary E46K disease mutation manifest the clinical picture of parkinsonism. How do we provide high resolution nanoimages of the GA during disease to capture dysfunction? Could we visualize the aSyn traffic jam between vesicles in the organelles ER and GA? OSB is emerging as a field as more technology advances and is more accessible. Structural studies of the GA will advance the field of neurological disease forward with an in depth understanding of dysfunction, fragmentation, and defects. Discoveries of the GA in PD, NDDs, and cancer would break new ground and provide translational medicine data of these diseases. Future research could be visualizing high angle annular dark field-STEM (HAADF-STEM) tomograms, cryogenic electron tomography (cryo-ET), multiplex correlative light and electron microscopy (cryo-CLEM), nanobody-assisted tissue immunostaining for volumetric EM (NATIVE) and using soft X-ray tomography (SXT) and computational reconstruction of the GA.

show abstract

Potential therapies and diagnosis based on Golgi-targeted nano drug delivery systems

Cited by 32 publications

References 88 publications

Sequential Drug Delivery in Targeted Cancer Therapy

Sequential Drug Delivery in Targeted Cancer Therapy

Pioneering Organelle Structural Biology: Golgi Apparatus Dysfunction in Parkinson’s Disease, Neurodevelopmental Disorders, and Cancer

Pioneering Organelle Structural Biology: Golgi Apparatus Dysfunction in Parkinson’s Disease, Neurodevelopmental Disorders, and Cancer

Contact Info

Product

Resources

About